Final Results - Part 3 of 3

AstraZeneca PLC
02 February 2006



AstraZeneca Development Pipeline
2 February 2006

Line Extensions

                   Compound             Mechanism                Area under         Phase         Estimated Filing
                                                               investigation                      MAA            NDA
               CV
               Atacand          angiotensin II antagonist  diabetic retinopathy      III         > 2008         >2008
               Crestor          statin                     atherosclerosis           III         1H 2007       1H 2007
               Crestor          statin                     outcomes CHF              III         >2008          >2008
               Crestor          statin                     outcomes renal            III          2008          2008
               Seloken/         beta-blocker               HCTZ combination          III        Launched        Filed
               Toprol-XL
               Exanta           thrombin inhibitor         prevention of stroke      III        Filed**        Filed*
                                                           in AF
               GI
               Nexium           proton pump inhibitor      NSAID GI side effects     III     Promotable***      Filed
                                                           - symptom resolution
               Nexium           proton pump inhibitor      NSAID GI side effects     III        Launched        Filed
                                                           - ulcer healing
               Nexium           proton pump inhibitor      peptic ulcer bleeding     III         >2008          >2008
               Nexium Sachet    proton pump inhibitor      GERD                      III        Q4 2006         Filed
               formulation
               Nexium           proton pump inhibitor      extra-oesophageal         II          >2008          >2008
                                                           reflux disease
               Neuroscience
               Seroquel SR      D2/5HT2 antagonist         schizophrenia             III        3Q 2006        3Q 2006
               Seroquel         D2/5HT2 antagonist         bipolar maintenance       III        2H 2007        1H 2007
               Seroquel         D2/5HT2 antagonist         bipolar depression        III        1H 2007         Filed
               Seroquel SR      D2/5HT2 antagonist         generalised anxiety       III          2008         2H 2007
                                                           disorder
               Seroquel SR      D2/5HT2 antagonist         major depressive          III          2008          2008
                                                           disorder
               Onc/infection
               Merrem           carbapenem antibiotic      skin and soft tissue      III                      Launched
                                                           infections
               Faslodex         oestrogen receptor         2nd line after            III          2008          2008
                                antagonist                 aromatase inhibitor
                                                           failure
               Faslodex         oestrogen receptor         1st line advanced         III          >2008         >2008
                                antagonist                 breast cancer
               Faslodex         oestrogen receptor         adjuvant                  III          >2008         >2008
                                antagonist
               Iressa           EGFR-TK inhibitor          head & neck cancer        III         2H 2007        1H 2007
               Iressa           EGFR-TK inhibitor          breast cancer             II           >2008         >2008

*AstraZeneca continues discussions with the FDA but the current assessment is
that it is unlikely a way forward or Exanta registration in the US will be 
identified.

** Switch to EU centralised procedure

*** Authorities stated these symptoms were already captured within the GERD
label. Text stating 'No clinical interaction with naproxen or rofecoxib' was 
approved.



                   Compound              Mechanism                Area under         Phase        Estimated Filing
                                                                investigation                      MAA           NDA
              Respiratory
              Symbicort          inhaled steroid/fast       Symbicort Maintenance     III         Filed
              Turbuhaler         onset, long-acting ss2     and Reliever Therapy
                                 agonist                    for asthma (SMART)
              Symbicort pMDI     inhaled steroid/fast       asthma                    III        Filed*         Filed
                                 onset, long-acting ss2
                                 agonist
              Symbicort pMDI     inhaled steroid/fast       COPD                      III        Filed*         2008
                                 onset, long-acting ss2
                                 agonist

* To be supplemented in 2008 with data supporting two additional strengths.


NCE's


Phase III

Compound                        Mechanism                 Area under          Phase          Estimated Filing
                                                         investigation                        MAA           NDA
CV
Galida                 PPAR agonist                 diabetes /metabolic        III         2H 2007*       2H2007*
                                                    syndrome

AGI-1067               Anti-atherogenitic           atherosclerosis            III         1H 2007       1H 2007
(Atherogenics)
AZD6140                ADP receptor antagonist      arterial thrombosis        III          >2008         >2008
Neuroscience
NXY-059 (Cerovive)     free radical trapping agent  stroke                     III         1H 2007       1H 2007

Oncology/Inf
Zactima                VEGF/EGF TKI inhibitor with  NSCLC                      III          >2008         >2008
                       RET kinase activity
(ZD6474)
AZD2171                 VEGF signalling inhibitor                             II/III        >2008         >2008
                       (VEGFR-TKI)
                                                    NSCLC and CRC


* Subject to the results of Phase III studies and regulatory discussions


NCE's

Phases I and II

       Compound                 Mechanism                 Area under          Phase          Estimated Filing
                                                         investigation                       MAA           NDA
CV
AZD7009                antiarrhythmic IV            atrial fibrillation -       II          2008           2008
                                                    conversion
AZD9684                CPU inhibitor                thrombosis                  II          >2008         >2008
AZD0837                thrombin inhibitor           thrombosis                  II          >2008         >2008
AZD2479 (Avanir)       Reverse Cholesterol          dyslipidaemia               I           >2008         >2008
                       Transport enhancer
AZD6610                                             dyslipidaemia/              I           >2008         >2008
                                                    diabetes
AZD8677                                             dyslipidaemia/              I           >2008         >2008
                                                    diabetes
GI
AZD9056                Ion channel blocker           inflammatory bowel         II          >2008         >2008
                                                    disease
AZD3355                inhibitor of transient lower  GERD                       I           >2008         >2008
                       oesophageal sphincter
                       relaxations  (TLESR)
AZD9343                inhibitor of transient lower GERD                        I           >2008         >2008
                       oesophageal sphincter
                       relaxations  (TLESR)
AZD9272                                             GERD                         I          >2008         >2008
Neuroscience

AZD3480                Neuronal nicotinic receptor  cognitive disorders         II          >2008         >2008
(TC-1734,Targacept)    agonist
AZD9272                                             neuropathic pain            I           >2008         >2008
Onc/Infection

Zactima                VEGF/EGF TKI inhibitor with  medullary thyroid           II          >2008         >2008
                       RET kinase activity          cancer
(ZD6474)
CytoFab (Protherics)   anti-TNF-alpha polyclonal    severe sepsis               II          >2008         >2008
                       antibody
ZD4054                 endothelin A receptor        prostate cancer             II          >2008         >2008
                       antagonist
Patrin  (KuDOS)        AGT inhibitor                solid tumours               II          >2008         >2008
AZD0530                SRC kinase inhibitor         solid tumours and           I           >2008         >2008
                                                    haematological
                                                    malignancies
AZD6244                MEK  inhibitor               solid tumours               I           >2008         >2008
(ARRY-142886)
AZD1152                Aurora kinase inhibitor      solid tumours and           I           >2008         >2008
                                                    haematological
                                                    malignancies
AZD4769                                             solid tumours               I           >2008         >2008
KU59436 (KuDOS)        PARP inhibitor               breast cancer               I           >2008         >2008
AQ4N (KuDOS)           Hypoxia activated cytotoxic  solid tumours               I           >2008         >2008


Phases I and II (continued)

       Compound                 Mechanism                 Area under          Phase          Estimated Filing
                                                         investigation                       MAA           NDA
Respiratory
AZD9056                ion channel blocker          rheumatoid arthritis        II          >2008         >2008
AZD9056                ion channel blocker          COPD                        II          >2008         >2008
AZD8955                collagenase inhibitor        osteoarthritis              II          >2008         >2008
AZD3778                chemokine receptor           rhinitis                    II          >2008         >2008
                       antagonist
AZD8309                chemokine receptor           rheumatoid arthritis        I           >2008         >2008
                       antagonist
AZD8309                chemokine receptor           COPD                        I           >2008         >2008
                       antagonist
AZD3342                protease inhibitor           COPD                        I           >2008         >2008
AZD1981                                             asthma                      I           >2008         >2008


NCE's


Pre Clinical

       Compound                 Mechanism            Area of investigation    Phase          Estimated Filing
                                                                                             MAA           NDA
CV

AZD8450                                             dyslipidaemia               PC          >2008         >2008
AZD6370                                             diabetes                    PC          >2008         >2008
AZD8593                                             haemostasis                 PC          >2008         >2008
AZD1175                                             diabetes/obesity            PC          >2008         >2008
AZD2207                                             diabetes/obesity            PC          >2008         >2008
AZD1305                                             arrhythmias                 PC          >2008         >2008
AZD1092                                             diabetes                    PC          >2008         >2008
AZD4121                                             dyslipidaemia               PC          >2008         >2008
GI

AZD8081                                             functional GI disease       PC          >2008         >2008
AZD6538                                             GERD                        PC          >2008         >2008
Neuroscience

AZD3102                                             Alzheimer's disease         PC          >2008         >2008
AZD1080                                             Alzheimer's disease         PC          >2008         >2008
AZD2327                                             anxiety                     PC          >2008         >2008
AZD5904                                             multiple sclerosis          PC          >2008         >2008
AZD6538                                             neuropathic pain            PC          >2008         >2008
AZD8797                                             multiple sclerosis          PC          >2008         >2008
AZD3783                                             anxiety and depression      PC          >2008         >2008
AZD1940                                             nociceptive and             PC          >2008         >2008
                                                    neuropathic pain.
AZD9335                                             neuropathic pain            PC          >2008         >2008
AZD3241                                             Parkinson's disease         PC          >2008         >2008


Pre Clinical (continued)

Compound                        Mechanism            Area of investigation    Phase          Estimated Filing
                                                                                             MAA           NDA
Onc/Infection

AZD9935                VEGF signalling inhibitor    solid tumours               PC          >2008         >2008
                       (VEGFR-TKI)
AZD0424                SRC kinase inhibitor         solid tumours               PC          >2008         >2008
AZD8931                                             solid tumours               PC          >2008         >2008
AZD4877                                             solid tumours               PC          >2008         >2008
AZD7762                                             solid tumours               PC          >2008         >2008
AZD5180 (Abgenix)                                   solid tumours               PC          >2008         >2008
AZD1845                                             solid tumours               PC          >2008         >2008
AZD8330                                             solid tumours               PC          >2008         >2008
AZD3646                                             solid tumours and           PC          >2008         >2008
                                                    haematological
                                                    malignancies
Respiratory

AZD6067                protease inhibitor           COPD                        PC          >2008         >2008
AZD6703                                             rheumatoid arthritis        PC          >2008         >2008
AZD6357                                             Osteoarthritis              PC          >2008         >2008
AZD7928                                             COPD                        PC          >2008         >2008
AZD2914                                             COPD                        PC          >2008         >2008
AZD2392                                             asthma/rhinitis             PC          >2008         >2008
AZD1744                                             asthma/rhinitis             PC          >2008         >2008
AZD5672                                             rheumatoid arthritis        PC          >2008         >2008
AZD3825                                             asthma                      PC          >2008         >2008
AZD1236                                             COPD                        PC          >2008         >2008
AZD4818                                             COPD                        PC          >2008         >2008
AZD5069                                             COPD                        PC          >2008         >2008
AZD9668                                             COPD                        PC          >2008         >2008
AZD9215                                             asthma                      PC          >2008         >2008
AZD1678                                             asthma                      PC          >2008         >2008
AZD6605                                             osteoarthritis              PC          >2008         >2008



AstraZeneca Development Pipeline
Discontinued Projects vs HY 28 July 05


 CV
    NCE/Line Extension                    Compound                        Area under investigation
NCE                         AZD7009 Antiarrythmic oral           atrial fibrillation - maintenance
NCE                         AZD7806                              dyslipidaemia
NCE                         AZD4619                              dyslipidaemia
NCE                         AZD8294                              dyslipidaemia


 Neuroscience
    NCE/Line Extension                    Compound                        Area under investigation
NCE                         AZD7371                              overactive bladder
NCE                         AZD4282                              neuropathic pain


 Oncology and Infection
    NCE/Line Extension                    Compound                        Area under investigation
NCE                         AZD3409                              solid tumours
NCE                         AZD5438                              solid tumours
NCE                         ZD6126                               solid tumours
NCE                         AZD4440                              solid tumours


  Respiratory and Inflammation
    NCE/Line Extension                    Compound                        Area under investigation
NCE                         AZD3778                              Indication asthma


Comments

As disclosure of compound information is balanced by the business need to
maintain confidentiality,

information in relation to some compounds listed here has not been disclosed at
this time.


Compounds in development are displayed by phase.


Abbreviations:



PC - Pre-clinical: Candidate Drug accepted for development but not yet
     administered to man.
MAA - Marketing Authorisation Application (Europe)
NDA - New Drug Application (USA)


                      This information is provided by RNS
            The company news service from the London Stock Exchange